143 related articles for article (PubMed ID: 26774883)
101. Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer.
Nakamura H; Taguchi M; Kitamura H; Nishikawa J
Gen Thorac Cardiovasc Surg; 2008 Aug; 56(8):404-9. PubMed ID: 18696206
[TBL] [Abstract][Full Text] [Related]
102. Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?
Hillner BE; Tosteson AN; Song Y; Tosteson TD; Onega T; Goodman DC; Siegel BA
J Am Coll Radiol; 2012 Jan; 9(1):33-41. PubMed ID: 22221634
[TBL] [Abstract][Full Text] [Related]
103. Trends in surveillance for resected colorectal cancer, 2001-2009.
Paulson EC; Veenstra CM; Vachani A; Ciunci CA; Epstein AJ
Cancer; 2015 Oct; 121(19):3525-33. PubMed ID: 26079928
[TBL] [Abstract][Full Text] [Related]
104. The reliability and validity of lung cancer and melanoma clinical quality survival measures.
Pendl-Robinson E; Calkins KL; Simon SE; Barrett K; Poznyak D
Health Serv Res; 2023 Oct; 58(5):1131-1140. PubMed ID: 37669902
[TBL] [Abstract][Full Text] [Related]
105. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER).
Skougaard K; Østrup O; Guldbrandsen K; Sørensen B; Meldgaard P; Saghir Z; Gørtz P; Lonsdale MN; Frank MS; Gerke O; Rychwicka-Kielek BA; Persson G; Land LH; Schytte T; Bodtger U; Skuladottir H; Søgaard J; Nielsen SS; Rasmussen TR; Fischer BM
Clin Lung Cancer; 2020 Mar; 21(2):e61-e64. PubMed ID: 31839533
[TBL] [Abstract][Full Text] [Related]
106. Associations between cancer-related information seeking and receiving PET imaging for routine cancer surveillance--an analysis of longitudinal survey data.
Tan AS; Gibson L; Zafar HM; Gray SW; Hornik RC; Armstrong K
Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):481-9. PubMed ID: 24550351
[TBL] [Abstract][Full Text] [Related]
107. Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors.
Malhotra J; Jabbour SK; Pine S
Transl Lung Cancer Res; 2019 Dec; 8(Suppl 4):S347-S350. PubMed ID: 32038912
[No Abstract] [Full Text] [Related]
108. Diagnostic performance of a deep-learning model using
Sung C; Oh JS; Park BS; Kim SS; Song SY; Lee JJ
Ann Nucl Med; 2024 Jul; 38(7):516-524. PubMed ID: 38589677
[TBL] [Abstract][Full Text] [Related]
109. Compliance and initiative: A discussion on the relationship between standards and activities in radiopharmaceutical production.
Silva Costa GA; Silva JMA; Soares RG; Modena CM; Oliveira FG; Lima FPA
Heliyon; 2024 Feb; 10(4):e26003. PubMed ID: 38384521
[TBL] [Abstract][Full Text] [Related]
110. Use of [
Guldbrandsen KF; Sopina L; Rasmussen TR; Fischer BM
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38275480
[TBL] [Abstract][Full Text] [Related]
111. Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.
Caswell-Jin JL; Callahan A; Purington N; Han SS; Itakura H; John EM; Blayney DW; Sledge GW; Shah NH; Kurian AW
JCO Clin Cancer Inform; 2021 May; 5():600-614. PubMed ID: 34043432
[TBL] [Abstract][Full Text] [Related]
112. PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer.
Bang A; Schoenfeld JD; Sun AY
Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S139-S146. PubMed ID: 31673518
[TBL] [Abstract][Full Text] [Related]
113. Choosing wisely in oncology: necessity and obstacles.
Saletti P; Sanna P; Gabutti L; Ghielmini M
ESMO Open; 2018; 3(5):e000382. PubMed ID: 30018817
[TBL] [Abstract][Full Text] [Related]
114. Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.
Erb CT; Su KW; Soulos PR; Tanoue LT; Gross CP
Lung Cancer; 2016 Sep; 99():200-7. PubMed ID: 27565940
[TBL] [Abstract][Full Text] [Related]
115. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
[TBL] [Abstract][Full Text] [Related]
116. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
117. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
118. The lung cancers: staging and response, CT,
Owens C; Hindocha S; Lee R; Millard T; Sharma B
Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
[TBL] [Abstract][Full Text] [Related]
119. Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer.
Veenstra CM; Vachani A; Ciunci CA; Zafar HM; Epstein AJ; Paulson EC
J Am Coll Radiol; 2016 May; 13(5):491-6. PubMed ID: 26774883
[TBL] [Abstract][Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
